Science Explorer Back to mapMap
Discussion
Company · Palo Alto · United States

Eiger Biopharmaceuticals (United States)

eigerbio.comROR OpenAlex
Research works
25
▲ 103% vs 2018-21
Citations
608
24.4 per fractional work
Top-10% rate
8.9%
all institutions 10.0%
Open access
30%
world 40%
International
18%
world 18%
Eiger Biopharmaceuticals (United States)

Not ranked overall: Eiger Biopharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Eiger Biopharmaceuticals (United States) work in?

In all years, 39% of research at Eiger Biopharmaceuticals (United States) is in Health Sciences, 30% in Physical Sciences. Its largest fields are Medicine (32%), Engineering (16%), Biochemistry, Genetics and Molecular Biology (11%). It does 1.4× the world's share of Health Sciences.

Health Sciences: 10 fractional works · 38.8% of its workMedicine: 8 fractional works · 32.0% of its workEpidemiology: 1 fractional works · 4.9% of its workPhysiology: 1 fractional works · 4.0% of its workEndocrinology, Diabetes and Metabolism: 1 fractional works · 3.1% of its workInfectious Diseases: 1 fractional works · 2.9% of its workBiochemistry: 1 fractional works · 2.7% of its workPulmonary and Respiratory Medicine: 1 fractional works · 2.7% of its workSurgery: 1 fractional works · 2.7% of its workHepatology: 1 fractional works · 2.4% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 2.1% of its workDermatology: 0 fractional works · 1.3% of its workRehabilitation: 0 fractional works · 1.1% of its workHematology: 0 fractional works · 0.7% of its workRheumatology: 0 fractional works · 0.7% of its workPharmacology: 0 fractional works · 0.5% of its workPsychiatry and Mental health: 0 fractional works · 0.3% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 0.3% of its workHealth Professions: 2 fractional works · 6.5% of its workGeneral Health Professions: 1 fractional works · 2.5% of its workRadiological and Ultrasound Technology: 0 fractional works · 2.0% of its workMedical Laboratory Technology: 0 fractional works · 1.3% of its workEmergency Medical Services: 0 fractional works · 0.7% of its workNursing: 0 fractional works · 0.3% of its workIssues, ethics and legal aspects: 0 fractional works · 0.3% of its workPhysical Sciences: 8 fractional works · 30.3% of its workEngineering: 4 fractional works · 16.4% of its workCivil and Structural Engineering: 2 fractional works · 9.4% of its workArchitecture: 0 fractional works · 2.0% of its workIndustrial and Manufacturing Engineering: 0 fractional works · 2.0% of its workMechanical Engineering: 0 fractional works · 1.3% of its workBiomedical Engineering: 0 fractional works · 0.7% of its workBuilding and Construction: 0 fractional works · 0.7% of its workAerospace Engineering: 0 fractional works · 0.3% of its workComputer Science: 2 fractional works · 7.5% of its workInformation Systems: 1 fractional works · 4.0% of its workComputer Science Applications: 0 fractional works · 2.0% of its workComputational Theory and Mathematics: 0 fractional works · 1.5% of its workMathematics: 1 fractional works · 3.0% of its workNumerical Analysis: 0 fractional works · 1.3% of its workTheoretical Computer Science: 0 fractional works · 1.0% of its workApplied Mathematics: 0 fractional works · 0.7% of its workChemical Engineering: 0 fractional works · 2.0% of its workChemical Health and Safety: 0 fractional works · 2.0% of its workMaterials Science: 0 fractional works · 1.3% of its workMaterials Chemistry: 0 fractional works · 1.3% of its workLife Sciences: 4 fractional works · 17.8% of its workBiochemistry, Genetics and Molecular Biology: 3 fractional works · 11.3% of its workMolecular Biology: 2 fractional works · 7.1% of its workCancer Research: 1 fractional works · 3.6% of its workCell Biology: 0 fractional works · 0.7% of its workAgricultural and Biological Sciences: 1 fractional works · 3.1% of its workPlant Science: 1 fractional works · 2.9% of its workFood Science: 0 fractional works · 0.2% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 3.1% of its workPharmaceutical Science: 1 fractional works · 2.7% of its workPharmacology: 0 fractional works · 0.4% of its workImmunology and Microbiology: 0 fractional works · 0.3% of its workImmunology: 0 fractional works · 0.3% of its workSocial Sciences: 3 fractional works · 13.1% of its workDecision Sciences: 1 fractional works · 4.7% of its workStatistics, Probability and Uncertainty: 1 fractional works · 4.7% of its workSocial Sciences: 1 fractional works · 4.3% of its workAnthropology: 0 fractional works · 1.0% of its workEducation: 0 fractional works · 1.0% of its workSociology and Political Science: 0 fractional works · 1.0% of its workDemography: 0 fractional works · 0.7% of its workGender Studies: 0 fractional works · 0.3% of its workPublic Administration: 0 fractional works · 0.3% of its workArts and Humanities: 0 fractional works · 2.0% of its workLanguage and Linguistics: 0 fractional works · 2.0% of its workEconomics, Econometrics and Finance: 0 fractional works · 1.3% of its workEconomics and Econometrics: 0 fractional works · 1.3% of its workPsychology: 0 fractional works · 0.4% of its workClinical Psychology: 0 fractional works · 0.4% of its workBusiness, Management and Accounting: 0 fractional works · 0.3% of its workStrategy and Management: 0 fractional works · 0.3% of its workALL ITS WORKEigerBiopharmaceutica…25fractional works, all years
Life Sciences18%Physical Sciences30%Health Sciences39%Social Sciences13%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 18 fields, with their numbers
    1. Medicine832.0%
    2. Health Professions26.5%
    3. Nursing00.3%
    1. Engineering416.4%
    2. Computer Science27.5%
    3. Mathematics13.0%
    4. Chemical Engineering02.0%
    5. Materials Science01.3%
    1. Biochemistry, Genetics and Molecular Biology311.3%
    2. Agricultural and Biological Sciences13.1%
    3. Pharmacology, Toxicology and Pharmaceutics13.1%
    4. Immunology and Microbiology00.3%
    1. Decision Sciences14.7%
    2. Social Sciences14.3%
    3. Arts and Humanities02.0%
    4. Economics, Econometrics and Finance01.3%
    5. Psychology00.4%
    6. Business, Management and Accounting00.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 0.63× its world share, 0 worksBiochemistry, Geneti…Computer Science: 2.59× its world share, 1 worksComputer ScienceEngineering: 1.34× its world share, 1 worksEngineeringHealth Professions: 1.02× its world share, 0 worksHealth ProfessionsMedicine: 1.76× its world share, 2 worksMedicineNursing: 2.75× its world share, 0 worksNursingDecision Sciences: 1.74× its world share, 0 worksDecision SciencesSocial Sciences: 1.33× its world share, 1 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Nursing, 2.8×. Every wedge is a field page.

All 8 fields, with their numbers
  1. Nursing2.75×0 works
  2. Computer Science2.59×1 works
  3. Medicine1.76×2 works
  4. Decision Sciences1.74×0 works
  5. Engineering1.34×1 works
  6. Social Sciences1.33×1 works
  7. Health Professions1.02×0 works
  8. Biochemistry, Genetics and Molecular Biology0.63×0 works

What are the most cited papers from Eiger Biopharmaceuticals (United States)?

The most cited paper from Eiger Biopharmaceuticals (United States) is "A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures" (Kenneth H. Dinnon, Sarah R. Leist, Alexandra Schäfer et al., 2020), with 690 citations. Next come "Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial" (241) and "Early Treatment with Pegylated Interferon Lambda for Covid-19" (179).

Most cited papers
#PaperReleasedCitations
1 A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures Kenneth H. Dinnon, Sarah R. Leist, Alexandra Schäfer et al. · Nature Open access 27 Aug 2020 690
2 Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial Jordan J. Feld et al. · The Lancet Respiratory Medicine Open access 7 Feb 2021 241
3 Early Treatment with Pegylated Interferon Lambda for Covid-19 Gilmar Reis et al. · New England Journal of Medicine Open access 8 Feb 2023 179
4 Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II Rachael Elizabeth Hawtin, David E. Stockett, Jo Ann W. Byl et al. · PLoS ONE Open access 15 Apr 2010 150
5 Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial Prasanna K. Jagannathan et al. · Nature Communications Open access 30 Mar 2021 149
All 50 most cited papers, with filters and sorting

Which keywords describe research at Eiger Biopharmaceuticals (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Antioxidants, DNA Damage, Risk Assessment, Immune Response, Sensitivity Analysis, Accident Prevention, Safety Culture and Oxidative Stress.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 9 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 9 words, with their numbers
  1. Antioxidants1▲ 13×5 topics
  2. DNA Damage1▲ 41×3 topics
  3. Epidemiology1▲ 1.33×9 topics
  4. Oxidative Stress1▲ 2.9×4 topics
  5. Immune Response1▲ 7.5×3 topics
  6. Risk Assessment1▲ 8.3×2 topics
  7. Sensitivity Analysis1▲ 36×2 topics
  8. Accident Prevention1▲ 65×2 topics
  9. Safety Culture1▲ 65×2 topics

Which research topics does Eiger Biopharmaceuticals (United States) publish most on?

By volume in 2022-now: Lysosomal Storage Disorders Research, Software Engineering Research, Open Source Software Innovations and Structural Analysis of Composite Materials.

Lysosomal Storage Disord…1Lysosomal Storage Disorders Research: 1 fractional worksSoftware Engineering Research: 0 fractional worksOpen Source Software Innovations: 0 fractional worksStructural Analysis of Composite Materials: 0 fractional worksStructural Analysis and Optimization: 0 fractional worksStructural Engineering a…0Structural Engineering and Vibration Analysis: 0 fractional worksProtease and Inhibitor Mechanisms: 0 fractional worksIslamic Finance and Communication: 0 fractional worksEducation and Communication Studies: 0 fractional worksBone fractures and treatments: 0 fractional works
PhysiologyInformation SystemsComputer Science ApplicationsMechanical Engineering5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Lysosomal Storage Disorders Research Physiology 1 works
  2. 2 Software Engineering Research Information Systems 0 works
  3. 3 Open Source Software Innovations Computer Science Applications 0 works
  4. 4 Structural Analysis of Composite Materials Mechanical Engineering 0 works
  5. 5 Structural Analysis and Optimization Civil and Structural Engineering 0 works
  6. 6 Structural Engineering and Vibration Analysis Civil and Structural Engineering 0 works
  7. 7 Protease and Inhibitor Mechanisms Cancer Research 0 works
  8. 8 Islamic Finance and Communication Sociology and Political Science 0 works
  9. 9 Education and Communication Studies Education 0 works
  10. 10 Bone fractures and treatments Epidemiology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available29.5%not open70.5%

World: 40% of research is openly available.

with international co-authors17.9%domestic only82.1%

World: 18% is written across borders.

How has Eiger Biopharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 103% higher than in 2018-2021.

1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Eiger Biopharmaceuticals (United States) as a percentage of every work published that year, 0.000040% in 2023.

0.00010%0.00020%0.00030%Eiger Biopharmaceuticals (United States)0.000032% in 20241990200020102020

Fractional works of Eiger Biopharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Palo Alto

All research institutions in Palo Alto

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Eiger Biopharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.